Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study
Identificadores
Identificadores
Fecha de publicación
2012Título de revista
ONCOLOGIST
Tipo de contenido
Artigo